» Articles » PMID: 33784238

Group Phenotypic Composition in Cancer

Overview
Journal Elife
Specialty Biology
Date 2021 Mar 30
PMID 33784238
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Although individual cancer cells are generally considered the Darwinian units of selection in malignant populations, they frequently act as members of groups where fitness of the group cannot be reduced to the average fitness of individual group members. A growing body of studies reveals limitations of reductionist approaches to explaining biological and clinical observations. For example, induction of angiogenesis, inhibition of the immune system, and niche engineering through environmental acidification and/or remodeling of extracellular matrix cannot be achieved by single tumor cells and require collective actions of groups of cells. Success or failure of such group activities depends on the phenotypic makeup of the individual group members. Conversely, these group activities affect the fitness of individual members of the group, ultimately affecting the composition of the group. This phenomenon, where phenotypic makeup of individual group members impacts the fitness of both members and groups, has been captured in the term 'group phenotypic composition' (GPC). We provide examples where considerations of GPC could help in understanding the evolution and clinical progression of cancers and argue that use of the GPC framework can facilitate new insights into cancer biology and assist with the development of new therapeutic strategies.

Citing Articles

Towards a new therapeutic approach based on selection for function in tumors: response to Dr. Mesut Tez.

Thomas F, DeGregori J, Marusyk A, Dujon A, Ujvari B, Capp J Evol Med Public Health. 2024; 12(1):260-261.

PMID: 39660278 PMC: 11631049. DOI: 10.1093/emph/eoae029.


Life history dynamics of evolving tumors: insights into task specialization, trade-offs, and tumor heterogeneity.

Ahmed M, Kim D Cancer Cell Int. 2024; 24(1):364.

PMID: 39506763 PMC: 11539310. DOI: 10.1186/s12935-024-03538-4.


A new perspective on tumor progression: Evolution via selection for function.

Thomas F, DeGregori J, Marusyk A, Dujon A, Ujvari B, Capp J Evol Med Public Health. 2024; 12(1):172-177.

PMID: 39364294 PMC: 11448472. DOI: 10.1093/emph/eoae021.


Modeling tumors as complex ecosystems.

Aguade-Gorgorio G, Anderson A, Sole R iScience. 2024; 27(9):110699.

PMID: 39280631 PMC: 11402243. DOI: 10.1016/j.isci.2024.110699.


The paradox of cooperation among selfish cancer cells.

Capp J, Thomas F, Marusyk A, Dujon A, Tissot S, Gatenby R Evol Appl. 2023; 16(7):1239-1256.

PMID: 37492150 PMC: 10363833. DOI: 10.1111/eva.13571.


References
1.
Sharma A, Cao E, Kumar V, Zhang X, Leong H, Wong A . Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. Nat Commun. 2018; 9(1):4931. PMC: 6250721. DOI: 10.1038/s41467-018-07261-3. View

2.
Greaves M . Cancer stem cells as 'units of selection'. Evol Appl. 2013; 6(1):102-8. PMC: 3567475. DOI: 10.1111/eva.12017. View

3.
Pepper J . Drugs that target pathogen public goods are robust against evolved drug resistance. Evol Appl. 2012; 5(7):757-61. PMC: 3492900. DOI: 10.1111/j.1752-4571.2012.00254.x. View

4.
Wagenblast E, Soto M, Gutierrez-Angel S, Hartl C, Gable A, Maceli A . A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015; 520(7547):358-62. PMC: 4634366. DOI: 10.1038/nature14403. View

5.
Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View